QPPV.COM KNOWLEDGE ASSESSMENT

Recombinant ADAMTS13: Immunogenicity, Neutralising Antibodies and Loss of Effect

Test your understanding of the concepts covered by Recombinant ADAMTS13: Immunogenicity, Neutralising Antibodies and Loss of Effect.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which description best reflects the EU product-information position as of the article's review date?
Question 2 of 10 A single ADAMTS13 activity result is lower than expected after a dose. Which approach is most appropriate before interpreting it as evidence of inhibitor-mediated loss of response?
Question 3 of 10 A global safety database receives a serious report from the EU after the US boxed warning has been approved. How should expectedness and regulatory interpretation be handled?
Question 4 of 10 A patient has a laboratory-confirmed neutralising antibody but no documented clinical deterioration, hospitalisation, or other serious outcome. Which statement about seriousness is most appropriate?
Question 5 of 10 Which set of reports is most appropriate to combine as a single coherent clinical phenotype in aggregate signal review?
Question 6 of 10 How should an EU pharmacovigilance team describe the September 2026 FDA monitoring instruction when communicating about the EU product information?
Question 7 of 10 A functional assay detects anti-ADAMTS13 neutralising activity after rADAMTS13 exposure, but the assay cannot distinguish antibodies to recombinant from endogenous ADAMTS13. Which conclusion is best supported?
Question 8 of 10 Why should a reviewer keep acquired immune-mediated TTP in mind when interpreting anti-ADAMTS13 findings in a person diagnosed with cTTP?
Question 9 of 10 The phase 3 study had very few acute TTP events in either treatment period. What conclusion about comparative acute-event prevention is most appropriate?
Question 10 of 10 Which follow-up request would most improve the interpretability of an ADAMTS13 activity result in a case report?

Select an answer to continue.

QPPV.com